These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 17373638)

  • 1. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
    Dejager S; Razac S; Foley JE; Schweizer A
    Horm Metab Res; 2007 Mar; 39(3):218-23. PubMed ID: 17373638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
    Pi-Sunyer FX; Schweizer A; Mills D; Dejager S
    Diabetes Res Clin Pract; 2007 Apr; 76(1):132-8. PubMed ID: 17223217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
    Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
    Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus.
    Kikuchi M; Abe N; Kato M; Terao S; Mimori N; Tachibana H
    Diabetes Res Clin Pract; 2009 Feb; 83(2):233-40. PubMed ID: 19118913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
    Kothny W; Foley J; Kozlovski P; Shao Q; Gallwitz B; Lukashevich V
    Diabetes Obes Metab; 2013 Mar; 15(3):252-7. PubMed ID: 23039321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
    Strain WD; Lukashevich V; Kothny W; Hoellinger MJ; Paldánius PM
    Lancet; 2013 Aug; 382(9890):409-416. PubMed ID: 23706759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
    Ristic S; Byiers S; Foley J; Holmes D
    Diabetes Obes Metab; 2005 Nov; 7(6):692-8. PubMed ID: 16219012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Goodman M; Thurston H; Penman J
    Horm Metab Res; 2009 May; 41(5):368-73. PubMed ID: 19221978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    Fonseca V; Schweizer A; Albrecht D; Baron MA; Chang I; Dejager S
    Diabetologia; 2007 Jun; 50(6):1148-55. PubMed ID: 17387446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.
    Foley JE; Bunck MC; Möller-Goede DL; Poelma M; Nijpels G; Eekhoff EM; Schweizer A; Heine RJ; Diamant M
    Diabetologia; 2011 Aug; 54(8):1985-91. PubMed ID: 21547496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.